Incidence and outcomes of thromboembolic and bleeding events in patients with liver cirrhosis in the USA

摘要

Abstract Background aims Understanding the epidemiology of bleeding and thromboembolism (clotting) in liver cirrhosis provides important data for future studies and policymaking; however, head‐to‐head comparisons of bleeding and clotting remain limited. Methods This is a populational retrospective cohort study using the US National Readmission Database of 2018 to compare the incidence and outcomes of bleeding and clotting events in patients with liver cirrhosis. The primary outcomes were the 11‐month incidence proportion of bleeding and clotting events. Results Of 1?304?815 participants, 26?569 had liver cirrhosis (45.0 women, mean age 57.2 SD, 12.7 years). During the 11‐month follow‐up, in patients with cirrhosis, for bleeding and clotting events, the incidence proportions was 15.3 and 6.6; the risk‐standardized all‐cause mortality rates were 2.4 and 1.0; the rates of intensive care intervention were 4.1 and 1.9; the rates of rehabilitation transfer were .2 and .2; the cumulative length of stays were 45?100 and 23?566?days; total hospital costs were 147 and 84 million US dollars; total hospital charges were 620 and 365 million US dollars. Compared to non‐cirrhosis, liver cirrhosis was associated with higher rates of bleeding (adjusted hazard ratio, 3.02 95 CI, 2.85–3.20) and portal vein thrombosis (PVT) (18.46 14.86–22.92), and slightly lower risks of other non‐PVT venous thromboembolic events (.82 .75–.89). Conclusions Bleeding is more common than thromboembolism in patients with liver cirrhosis, causes higher morbidity, mortality and resource utilization. Liver cirrhosis is an independent risk factor for bleeding and PVT, but not non‐PVT thromboembolism including venous thromboembolism, acute myocardial infarction and ischemic stroke.